Author:
Appelman Brent,Oppelaar Jetta J.,Broeders Lani,Wiersinga Willem Joost,Peters-Sengers Hessel,Vogt Liffert,Appelman Brent,Schinkel Michiel,Buis David,Sigaloff Kim C. E.,Elbers Paul W. G.,Rusch Daisy,Reidinga Auke,Moeniralam Hazra,Wyers Caroline,van den Bergh Joop,Simsek Suat,van Dam Bastiaan,van den Gritters Niels C.,Bokhizzou Nejma,Brinkman Kees,de Kruif Martijn,Dormans Tom,Douma Renée,de Haan Lianne R.,Fung Tsz Yeung,Beudel Martijn,
Abstract
AbstractChronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.
Funder
Amsterdam UMC Corona Fund
Publisher
Springer Science and Business Media LLC